Tumor Biology

, Volume 37, Issue 6, pp 8383–8390 | Cite as

Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer

  • Rong-liang Shi
  • Ning Qu
  • Tian Liao
  • Wen-jun Wei
  • Zhong-wu Lu
  • Ben Ma
  • Yu-Long Wang
  • Qing-hai Ji
Original Article


Current evidences suggest an influence of overweight body mass index (BMI) on the carcinogenesis in malignancies. However, the role of BMI is unclear in papillary thyroid cancer (PTC). The aim of the present study is to investigate the relationship between BMI and BRAF V600E mutation status in PTC. BRAF V600E mutation in 108 patients with PTC was analyzed by Sanger sequencing. The cutoff point of BMI was identified by X-tile for predicting mutation by overweight. Odds ratios (OR) and 95 % confidence interval (CI) of BRAF V600E mutation according to BMI and clinicopathologic variables were calculated using logistic regression models. Fifty-one patients were positive for BRAF V600E mutation. A positive relationship existed between BRAF V600E mutation and BMI (p = 0.039). A 24.3 kg/m2 was identified as cutoff point for differentiating greater than 52.0 % observed probability of mutation for BRAF V600E in entire cohort, which was similar to the midpoint between the upper limit of normal BMI and overweight defined by WHO (≥24 kg/m2). Multivariate analysis confirmed the association between BRAF V600E mutation with overweight BMI range (OR 7.645, 95 % CI 1.275–45.831, p = 0.026). This study suggests an influence of overweight BMI on the status of BRAF V600E in patients with PTC, whereas the underlying mechanism need to be further investigated.


Body mass index BRAF mutation Papillary thyroid cancer Overweight 



This work was supported by funds from the National Science Foundation of China (No. 81572622 and No. 81272934 to QHJ), the Shanghai Rising-Star Program (No. 15QA1401100 to YLW), and the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (to TL).

Compliance with ethical standards

Written informed consent from all the patients was provided. This study was approved by the Ethical Committee of the Shanghai Cancer Center of Fudan University.

Conflicts of interest



  1. 1.
    James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer—what is the risk factor? Eur J Cancer. 2015;51:705–20.CrossRefPubMedGoogle Scholar
  2. 2.
    Scarpa M, Ruffolo C, Erroi F, Fiorot A, Basato S, Pozza A, et al. Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case–control study. Anticancer Res. 2014;34:5735–41.PubMedGoogle Scholar
  3. 3.
    Ortiz-Mendoza CM, Velasco-Navarro C. [Obesity, a main risk factor for endometrial cancer]. Rev Med Inst Mex Seguro Soc. 2013;51:260–3.PubMedGoogle Scholar
  4. 4.
    Han JM, Kim TY, Jeon MJ, Yim JH, Kim WG, Song DE, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol. 2013;168:879–86.CrossRefPubMedGoogle Scholar
  5. 5.
    Anderson AS, Key TJ, Norat T, Scoccianti C, Cecchini M, Berrino F, et al. European code against cancer 4th edition: obesity, body fatness and cancer. Cancer Epidemiol. 2015;39 Suppl 1:S34–45.CrossRefPubMedGoogle Scholar
  6. 6.
    Gathirua-Mwangi WG, Zollinger TW, Murage MJ, Pradhan KR, Champion VL. Adult BMI change and risk of breast cancer: national health and nutrition examination survey (NHANES) 2005–2010. Breast Cancer. 2015;22:648–56.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hursting SD, Nunez NP, Patel AC, Perkins SN, Lubet RA, Barrett JC. The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat Res. 2005;576:80–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Azvolinsky A. Cancer prognosis: role of BMI and fat tissue. J Natl Cancer Inst. 2014;106:dju177.CrossRefPubMedGoogle Scholar
  9. 9.
    Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the ras/raf signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Sobin LHGM, Wittekind CH, UICC. TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009.Google Scholar
  13. 13.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Richter A, Grieu F, Carrello A, Amanuel B, Namdarian K, Rynska A, et al. A multisite blinded study for the detection of braf mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep. 2013;3:1659.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, Buchanan DD, Casey G, Cleary SP, Cotterchio M, Farris AB, Figueiredo JC, Gallinger S, Green RC, Haile RW, Hopper JL, Jenkins MA, Le Marchand L, Makar KW, McLaughlin JR, Potter JD, Renehan AG, Sinicrope FA, Thibodeau SN, Ulrich CM, Win AK, Lindor NM, Limburg PJ: Association between body mass index and mortality for colorectal cancer survivors: Overall and by tumor molecular phenotype. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015.Google Scholar
  16. 16.
    Brandstedt J, Wangefjord S, Nodin B, Eberhard J, Sundstrom M, Manjer J, et al. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PLoS ONE. 2014;9, e98964.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hughes LA, Williamson EJ, van Engeland M, Jenkins MA, Giles GG, Hopper JL, et al. Body size and risk for colorectal cancers showing braf mutations or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41:1060–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Clinical meaning of braf mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol. 2014;20:4370–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with cpg island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120:656–63.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang W, Bai X, Ge H, Cui H, Wei Z, Han G. Meta-analysis in the association between obesity and risk of thyroid cancer. Int J Clin Exp Med. 2014;7:5268–74.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Hou P, Liu D, Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer. 2011;18:687–97.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013;310:535.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Xing M. BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol. 2009;16:801–3.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer. 2008;15:183–90.CrossRefPubMedGoogle Scholar
  28. 28.
    Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, et al. Hypermethylation of the DNA mismatch repair gene hmlh1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer. 2008;113:247–55.CrossRefPubMedGoogle Scholar
  29. 29.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13:1341–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Eveleth PB, Andres R, Chumlea WC, Eiben O, Ge K, Harris T, et al. Uses and interpretation of anthropometry in the elderly for the assessment of physical status. Report to the nutrition unit of the world health organization: the expert subcommittee on the use and interpretation of anthropometry in the elderly. J Nutr Health Aging. 1998;2:5–17.PubMedGoogle Scholar
  31. 31.
    Joensuu K, Hagstrom J, Leidenius M, Haglund C, Andersson LC, Sariola H, et al. Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases—elevated bmi-1 expression in late breast cancer relapses. Virchows Arch. 2011;459:31–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (MCRC) patients treated with bevacizumab-based therapy. Med Oncol. 2013;30:679.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15:556–65.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Halnan KE. Influence of age and sex on incidence and prognosis of thyroid cancer. Three hundred forty-four cases followed for ten years. Cancer. 1966;19:1534–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Moreira Leite KR, de Araujo VC, Rezende Meirelles MI, Lopes Costa AD, Camara-Lopes LH. No relationship between proliferative activity and the macis prognostic scoring system in papillary thyroid carcinoma. Head Neck. 1999;21:602–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Rodriguez-Cuevas S, Labastida-Almendaro S, Cortes-Arroyo H, Lopez-Garza J, Barroso-Bravo S. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of ages, macis, and risk group scores in Mexican population. J Exp Clin Cancer Res. 2002;21:79–86.PubMedGoogle Scholar
  37. 37.
    Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMedGoogle Scholar
  38. 38.
    Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of braf mutation in thyroid cancer. Ann Surg. 2007;246:466–70. discussion 470–461.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hayes A, Gearon E, Backholer K, Bauman A, Peeters A. Age-specific changes in BMI and BMI distribution among Australian adults using cross-sectional surveys from 1980 to 2008. Int J Obes (Lond). 2015;39:1209–16.CrossRefGoogle Scholar
  40. 40.
    Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238–45.CrossRefPubMedGoogle Scholar
  41. 41.
    Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184–99.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Rong-liang Shi
    • 1
    • 2
    • 3
  • Ning Qu
    • 1
    • 2
  • Tian Liao
    • 1
    • 2
  • Wen-jun Wei
    • 1
    • 2
  • Zhong-wu Lu
    • 1
    • 2
  • Ben Ma
    • 1
    • 2
  • Yu-Long Wang
    • 1
    • 2
  • Qing-hai Ji
    • 1
    • 2
  1. 1.Department of Head and Neck SurgeryFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Department of General surgeryMinhang Hospital, Fudan UniversityShanghaiChina

Personalised recommendations